🎁 A holiday package to celebrate the season! Click here and shop now!

TextRanch

The best way to perfect your writing.

Discover why 1,062,726 users count on TextRanch to get their English corrected!

1. Input your text below.
2. Get it corrected in a few minutes by our editors.
3. Improve your English!

One of our experts will correct your English.

Our experts

dyslipidemia vs dyslipidaemia

Both "dyslipidemia" and "dyslipidaemia" are correct spellings of the medical term referring to abnormal levels of lipids in the blood. The spelling with 'emia' is more common in American English, while the spelling with 'aemia' is more common in British English. Both spellings are widely accepted and used in medical literature.

Last updated: March 27, 2024 • 991 views

dyslipidemia

This is a correct spelling of the medical term referring to abnormal levels of lipids in the blood. It is commonly used in American English.

This term is used to describe a condition characterized by abnormal levels of lipids (cholesterol and triglycerides) in the blood. It is commonly seen in medical contexts.

Examples:

  • The patient was diagnosed with dyslipidemia and prescribed medication to manage cholesterol levels.
  • Regular exercise and a healthy diet can help in the management of dyslipidemia.
  • Dyslipidemia is a risk factor for cardiovascular diseases.
  • The doctor recommended a lipid profile test to check for dyslipidemia.
  • Treatment for dyslipidemia may include statin medications.
  • Patients had a BMI >= 30 kg/ m² or BMI > 27 kg/ m² with hypertension and/ or dyslipidemia at inclusion.
  • This is accompanied by an increase in disorders such as high blood pressure, obesity and dyslipidemia, as well as smoking-related disorders.
  • Treatment of dyslipidemia Mixed dyslipidaemia characterised by hypertriglyceridaemia and/ or low HDL-cholesterol.
  • Consultation with standard guidelines for management of dyslipidaemia is recommended.
  • Mixed dyslipidaemia characterised by hypertriglyceridaemia and/ or low HDL-cholesterol.
  • Hypercholesterolemia still is an indication, but mainly in combination with such dyslipidaemia.
  • Pelzont was studied in four main studies in patients with hypercholesterolaemia or mixed dyslipidaemia.
  • Experience in pediatrics is limited to a small number of patients (age 4 - 17 years) with severe dyslipidemias, such as homozygous familial hypercholesterolemia.
  • In clinical studies, REYATAZ (with or without ritonavir) has been shown to induce dyslipidaemia to a lesser extent than comparators.
  • Weight loss induced by< Invented name > is accompanied by beneficial changes in serum lipids and glycaemic control in patients with dyslipidaemia and type 2 diabetes, respectively.
  • Treatment of primary hypercholesterolaemia or mixed dyslipidaemia, treatment of homozygous familial hypercholesterolaemia.
  • Combination antiretroviral therapy (CART), including REYATAZ (with or without ritonavir)-based CART, is associated with dyslipidaemia.
  • Crestor (rosuvastatin calcium) is a selective 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) that has been approved for use as a lipid-regulating agent in the management of patients with dyslipidaemia.
  • Lipid alterations should be managed as clinically appropriate, particularly in dyslipidemic patients and in patients with risk factors for the development of lipids disorders.
  • Pelzont is used in addition to diet and exercise in patients with dyslipidaemia (abnormally high levels of fat in the blood), particularly' combined mixed dyslipidaemia' and' primary hypercholesterolaemia'.
  • The Committee for Medicinal Products for Human Use (CHMP) decided that Pelzont's benefits are greater than its risks for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia and in patients with primary hypercholesterolaemia.
  • Pelzont is indicated for the treatment of dyslipidaemia, particularly in patients with combined mixed dyslipidaemia (characterised by elevated levels of LDL-cholesterol and triglycerides and low HDL-cholesterol) and in patients with primary hypercholesterolaemia (heterozygous familial and non-familial).
  • Tredaptive is used in addition to diet and exercise in patients with dyslipidaemia (abnormally high levels of fat in the blood), particularly' combined mixed dyslipidaemia' and' primary hypercholesterolaemia'.
  • Similarly, in obese patients with dylipidaemia, weight loss was associated with increases in HDL choleseterol of 12-22% and reductions in triglycerides of 9-21%.
  • Patients with combined mixed dyslipidaemia have high blood levels of' bad' LDL cholesterol and triglycerides (a type of fat), and low levels of' good' HDL cholesterol.

Alternatives:

  • hyperlipidemia
  • lipid disorder
  • abnormal lipid levels
  • high cholesterol
  • elevated triglycerides

dyslipidaemia

This is a correct spelling of the medical term referring to abnormal levels of lipids in the blood. It is commonly used in British English.

This term is used to describe a condition characterized by abnormal levels of lipids (cholesterol and triglycerides) in the blood. It is commonly seen in medical contexts.

Examples:

  • The patient was diagnosed with dyslipidaemia and prescribed medication to manage cholesterol levels.
  • Regular exercise and a healthy diet can help in the management of dyslipidaemia.
  • Dyslipidaemia is a risk factor for cardiovascular diseases.
  • The doctor recommended a lipid profile test to check for dyslipidaemia.
  • Treatment for dyslipidaemia may include statin medications.
  • Consultation with standard guidelines for management of dyslipidaemia is recommended.
  • recommended and therefore the use of gemfibrozil is primary reserved for those patients with dyslipidaemia characterised by high triglyceride levels and/ or low HDL cholesterol levels.
  • Pelzont was studied in four main studies in patients with hypercholesterolaemia or mixed dyslipidaemia.
  • Treatment of primary hypercholesterolaemia or mixed dyslipidaemia, treatment of homozygous familial hypercholesterolaemia.
  • Hypercholesterolemia Treatment of primary hypercholesterolemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.
  • Hypercholesterolemia Treatment of primary hypercholesterolemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.
  • Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non- pharmacological treatments (e. g. exercise, weight reduction) is inadequate.
  • Hypercholesterolaemia Treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e. g. exercise, weight reduction) is inadequate.
  • Treatment of dyslipidemia Mixed dyslipidaemia characterised by hypertriglyceridaemia and/ or low HDL-cholesterol.
  • Hypercholesterolemia still is an indication, but mainly in combination with such dyslipidaemia.
  • In clinical studies, REYATAZ (with or without ritonavir) has been shown to induce dyslipidaemia to a lesser extent than comparators.
  • Weight loss induced by< Invented name > is accompanied by beneficial changes in serum lipids and glycaemic control in patients with dyslipidaemia and type 2 diabetes, respectively.
  • Combination antiretroviral therapy (CART), including REYATAZ (with or without ritonavir)-based CART, is associated with dyslipidaemia.
  • Patients with combined mixed dyslipidaemia have high blood levels of' bad' LDL cholesterol and triglycerides (a type of fat), and low levels of' good' HDL cholesterol.
  • Patients with combined mixed dyslipidaemia have high blood levels of' bad' LDL cholesterol and triglycerides (a type of fat), and low levels of' good' HDL cholesterol.
  • Patients with type 2 diabetes often have dyslipidaemia (abnormal levels of fat in the blood), such as low levels of high-density lipoprotein (HDL or' good') cholesterol and high levels of triglycerides.
  • (used to treat dyslipidaemia) or sulfinpyrazone (used to treat chronic gout).
  • drug hypersensitivity central obesity, decreased appetite, diabetes mellitus, dyslipidaemia, hypercholesterolaemia, increased appetite
  • Crestor (rosuvastatin calcium) is a selective 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) that has been approved for use as a lipid-regulating agent in the management of patients with dyslipidaemia.
  • Pelzont is used in addition to diet and exercise in patients with dyslipidaemia (abnormally high levels of fat in the blood), particularly' combined mixed dyslipidaemia' and' primary hypercholesterolaemia'.

Alternatives:

  • hyperlipidaemia
  • lipid disorder
  • abnormal lipid levels
  • high cholesterol
  • elevated triglycerides

Related Comparisons

What Our Customers Are Saying

Our customers love us! We have an average rating of 4.79 stars based on 283,125 votes.
Also check out our 2,100+ reviews on TrustPilot (4.9TextRanch on TrustPilot).

Why choose TextRanch?

Lowest prices
Up to 50% lower than other online editing sites.

Fastest Times
Our team of editors is working for you 24/7.

Qualified Editors
Native English experts for UK or US English.

Top Customer Service
We are here to help. Satisfaction guaranteed!

×

💝 TextRanch Holidays Offer! 💝️

25% special discount
Stock up on credits for the entire year!

Grab this offer now!